333969-81-6 Usage
Chemical classification
Carboxylic acid derivative The compound is a derivative of carboxylic acid, which is an organic compound containing a carboxyl group (-COOH).
Core structure
Quinoline The core structure of the compound is quinoline, which is a heterocyclic aromatic compound with a benzene ring fused to a pyridine ring.
Attached group
Cyclohexylphenyl A cyclohexylphenyl group is attached to the quinoline core, which consists of a phenyl ring attached to a cyclohexane ring.
Pharmaceutical applications
Anti-inflammatory and antioxidant properties The compound has potential applications in the pharmaceutical industry due to its ability to reduce inflammation and protect cells from oxidative damage.
Fluorescent probe potential
Cellular imaging studies The quinoline core in the compound may allow it to be used as a fluorescent probe for cellular imaging, which can help visualize and study cellular processes.
Unique solubility and binding properties
Cyclohexylphenyl group The presence of the cyclohexylphenyl group may provide the compound with unique solubility and binding properties, which could be useful for targeting specific biological molecules or processes.
Further research potential
Additional uses and applications Further investigation into the properties and behavior of 2-(4-cyclohexylphenyl)quinoline-4-carboxylic acid may reveal more potential uses and applications in various scientific and industrial fields.
Check Digit Verification of cas no
The CAS Registry Mumber 333969-81-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,3,9,6 and 9 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 333969-81:
(8*3)+(7*3)+(6*3)+(5*9)+(4*6)+(3*9)+(2*8)+(1*1)=176
176 % 10 = 6
So 333969-81-6 is a valid CAS Registry Number.
333969-81-6Relevant articles and documents
Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase
Madak, Joseph T.,Cuthbertson, Christine R.,Miyata, Yoshinari,Tamura, Shuzo,Petrunak, Elyse M.,Stuckey, Jeanne A.,Han, Yanyan,He, Miao,Sun, Duxin,Showalter, Hollis D.,Neamati, Nouri
, p. 5162 - 5186 (2018/05/15)
We pursued a structure-guided approach toward the development of improved dihydroorotate dehydrogenase (DHODH) inhibitors with the goal of forming new interactions between DHODH and the brequinar class of inhibitors. Two potential residues, T63 and Y356, suitable for novel H-bonding interactions, were identified in the brequinar-binding pocket. Analogues were designed to maintain the essential pharmacophore and form new electrostatic interactions through strategically positioned H-bond accepting groups. This effort led to the discovery of potent quinoline-based analogues 41 (DHODH IC50 = 9.71 ± 1.4 nM) and 43 (DHODH IC50 = 26.2 ± 1.8 nM). A cocrystal structure between 43 and DHODH depicts a novel water mediated H-bond interaction with T63. Additional optimization led to the 1,7-naphthyridine 46 (DHODH IC50 = 28.3 ± 3.3 nM) that forms a novel H-bond with Y356. Importantly, compound 41 possesses significant oral bioavailability (F = 56%) and an elimination t1/2 = 2.78 h (PO dosing). In conclusion, the data supports further preclinical studies of our lead compounds toward selection of a candidate for early-stage clinical development.
